Acute Hemodynamic Effects of Conivaptan, a Dual V 1A and V 2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure
- 13 November 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 104 (20) , 2417-2423
- https://doi.org/10.1161/hc4501.099313
Abstract
Background Arginine vasopressin may contribute to abnormalities in hemodynamics and fluid balance in heart failure through its actions on V1A (vascular and myocardial effects) and V2 receptors (ren...Keywords
This publication has 15 references indexed in Scilit:
- The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failurePublished by Elsevier ,2010
- Vasopressin: A therapeutic target in congestive heart failure?Journal of Cardiac Failure, 1999
- Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captoprilJournal of the American College of Cardiology, 1994
- Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cellsBiochemical and Biophysical Research Communications, 1989
- Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: Comparison with the renin-angiotensin system and the sympathetic nervous systemJournal of the American College of Cardiology, 1986
- Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failureThe American Journal of Cardiology, 1985
- Role of Antidiuretic Hormone in Impaired Water Excretion of Patients with Congestive Heart Failure*Journal of Clinical Endocrinology & Metabolism, 1984
- Increased plasma arginine vasopressin levels in patients with congestive heart failureJournal of the American College of Cardiology, 1983
- Antidiuretic hormone in congestive heart failureThe American Journal of Medicine, 1982
- Plasma ADH Level in Patients with Chronic Congestive Heart FailureJapanese Circulation Journal, 1968